Literature DB >> 16888409

Expression of tumor-associated differentially expressed Gene-14 (TADG-14/KLK8) and its protein hK8 in uterine endometria and endometrial carcinomas.

Honghua Jin1, Nobutaka Nagai, Kazushi Shigemasa, Lijun Gu, Hirotoshi Tanimoto, Mayu Yunokawa, Koso Ohama, Yoshiki Kudo, Timothy J O'Brien.   

Abstract

To clarify the biological behavior of TADG-14/KLK8, we investigated TADG-14/KLK8 mRNA by semiquantitative RT-PCR and hK8 expression by immunohistochemistry using 37 normal endometria and 44 endometrial carcinoma tissues. TADG-14/KLK8 mRNA expression levels were significantly higher in proliferative compared to secretory phase endometria (p = 0.0143). Levels of TADG-14/KLK8 mRNA expression correlated with hK8 protein levels. hK8 was detected in 73.3% (11/15) of endometria with a significantly higher detection rate in the proliferative compared to secretory and atrophic phase endometria (p = 0.0002). High expression of hK8 was found in 61.4% of endometrial carcinomas compared to 35.1% of endometrial tissue samples (p = 0.0187). hK8 expression was significantly higher in stage I (p = 0.0433, 0.0038) and grade 1/2 (G1/2) of the tumors (p = 0.0195, 0.0044). We suggest that expression of TADG-14/KLK8may be regulated by sex steroid hormones in endometria. Our results indicate that elevated TADG-14/KLK8 expression is an early event in endometrial carcinogenesis, and may potentially serve as a useful early biomarker for the detection of endometrial carcinomas in menopausal women. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16888409     DOI: 10.1159/000094741

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  3 in total

1.  Human kallikrein 8 expression in salivary gland tumors.

Authors:  Mark R Darling; Sam Tsai; Linda Jackson-Boeters; Thomas D Daley; Eleftherios P Diamandis
Journal:  Head Neck Pathol       Date:  2008-07-03

2.  Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.

Authors:  Weiwei Gong; Yueyang Liu; Christof Seidl; Tobias Dreyer; Enken Drecoll; Matthias Kotzsch; Holger Bronger; Julia Dorn; Viktor Magdolen
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

3.  Increase of Serum Kallikrein-8 Level After Long-term Telbivudine Treatment.

Authors:  Haw-En Wang; Chih-Lang Lin; Tai-Long Pan; Chau-Ting Yeh
Journal:  In Vivo       Date:  2018 Jul-Aug       Impact factor: 2.155

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.